share_log

Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference

Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference

業績電話會議摘要 | ELSE NUTRITION HOLDINGS INC (BABYF.US) 2024 年第一季度業績發佈會
富途資訊 ·  05/19 04:45  · 電話會議

The following is a summary of the Else Nutrition Holdings Inc. (BABYF) Q1 2024 Earnings Call Transcript:

以下是Else Nutrition Holdings Inc.(BABYF)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Else Nutrition Holdings reported a Q1 2024 revenue of $2.1 million, a drop from $2.9 million in Q1 2023.

  • Despite a decrease in the quarter revenue due to anticipated customer deal delays, the company expects to see significant revenue growth throughout 2024.

  • The company saw a 92% increase in U.S. Amazon sales and a 330% increase in Canadian Amazon sales compared to the same period in 2023.

  • Else Nutrition Holdings報告稱,2024年第一季度收入爲210萬美元,低於2023年第一季度的290萬美元。

  • 儘管由於預期的客戶交易延遲,本季度收入有所下降,但該公司預計2024年全年收入將大幅增長。

  • 與2023年同期相比,該公司在美國的亞馬遜銷售額增長了92%,加拿大亞馬遜的銷售額增長了330%。

Business Progress:

業務進展:

  • Else Nutrition started 2024 on a high note, with several retail partner announcements and launching their kids ready-to-drink shakes in both vanilla and chocolate flavors.

  • They are preparing to introduce an adult ready-to-drink line.

  • With the commercial launch of their plant-based infant formula in Australia, they are entering a growing market.

  • They have secured three manufacturing partners and signed a powder manufacturing agreement to guarantee supply through the end of 2025.

  • A new marketing program is underway to broaden brand recognition and fuel growth.

  • They are continually liaising with the FDA for U.S. approval based on the rising global demand for plant-based products.

  • Else Nutrition在2024年開局時表現強勁,宣佈了幾家零售合作伙伴,並推出了香草和巧克力口味的兒童即飲奶昔。

  • 他們正準備推出成人即飲產品線。

  • 隨着其植物性嬰兒配方奶粉在澳大利亞的商業推出,他們正在進入一個不斷增長的市場。

  • 他們已經找到了三個製造合作伙伴,並簽署了粉末製造協議,以保證2025年底之前的供應。

  • 一項新的營銷計劃正在進行中,以擴大品牌知名度並推動增長。

  • 鑑於全球對植物基產品的需求不斷增加,他們一直在與美國食品藥品管理局聯絡,爭取美國的批准。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論